Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 10;4:950. doi: 10.1038/s42003-021-02481-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Crown 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a Left panel represents immunohistochemical staining of RHGP (n = 5) and DHGP (n = 5) chemonaïve CRCLM specimens using TGFβ1 antibody. The right panel shows the positivity [total number of positive pixels/total number of pixels] was measured using an optimized Aperio algorithm (mean + SD). b. Fluorescence in situ hybridization (FISH) for TGFβ1 mRNA (green) expression in chemonaïve CRCLM lesions overlapped with CK20 (cytokeratin 20, red) antibody. c The left panel shows immunohistochemistry staining of chemonaïve CRCLM lesions with TGFβRII antibody. The right panel shows the positivity [total number of positive pixels/total number of pixels] was measured using an optimized Aperio algorithm (mean + SD). d Western blot of RUNX1 in HT29 cancer cells upon treatment with recombinant TGFβ1 for 24 h (top panel). e Western blot of RUNX1 and TGFβRII in HT29 cancer cells expressing either scrambles shRNA or shRNA against TGFβRII in the presence or absence of recombinant TGFβ1 for 24 h (top panel). f Western blot of RUNX1 in HT29 and SW620 cancer cells in the presence or absence of recombinant TGFβ1 individually or TGFβ1 with 2 μM of TGFβRII inhibitor (ITD1) for 24 h (top panel). The bottom panels represent the intensity of the bands (n = 3). C-RHGP Central tumor cells in RHGP lesions, P-RHGP Peripheral tumor cells in RHGP lesions, A-RHGP Adjacent hepatocytes to tumor lesion in RHGP, D-RHGP Distal hepatocytes to tumor lesion in RHGP, C-DHGP Central tumor cells in DHGP, P-DHGP Peripheral tumor cells in DHGP lesions, A-DHGP Adjacent hepatocytes to tumor lesion in DHGP, D-DHGP Distal hepatocytes to tumor lesion in DHGP. Data are presented as the mean ± SD.